ACTICCA-1
What it tests: Adjuvant gemcitabine + cisplatin vs capecitabine in resected biliary tract cancer
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.